IVIG treatment for repeated hypothermic attacks associated with LGI1 antibody encephalitis
Citation Manager Formats
Make Comment
See Comments

Hypothermia, defined as a core body temperature of <35.0°C (<95.0°F), is a life-threatening and emergency situation. Various conditions and diseases can cause hypothermia, including environmental exposure, drug intoxication, CNS diseases, and metabolic abnormalities, such as hypopituitarism, hypoadrenalism, hypothyroidism, and hypoglycemia.
Leucine-rich glioma-inactivated 1 (LGI1) antibody–associated encephalitis is an autoimmune-mediated encephalitis in which autoantibodies are directed against a voltage-gated potassium channel (VGKC) complex protein named LGI1.1 The LGI1 protein is widely expressed in the neurons of the CNS and also in the hypothalamus.2 Central hypothermia associated with autoimmune-mediated encephalitis is rare; however, it is a potentially life-threatening symptom of encephalitis. Here, we describe a patient who experienced repeated hypothermic attacks associated with anti–LGI1 encephalitis.
Case report.
A 56-year-old Japanese man was admitted to our hospital with hypothermia and consciousness disturbance. He had been diagnosed with VGKC antibody encephalitis 1 year earlier based on the detection of VGKC-complex antibodies and neurologic symptoms. He was initially admitted to our hospital because of seizures and acute consciousness disturbances accompanied with a 6-month history of psychiatric symptoms, such as violent behavior toward his family, and audiovisual hallucinations since the summer of 2007. Brain MRI revealed a slightly hyperintense area in the right medial temporal region at the initial admission to our hospital. The findings of whole-body CT and routine CSF analysis were normal. Corticosteroid treatment enhanced his psychiatric symptoms. He was transferred to a psychiatric hospital because of the continuing psychiatric symptoms which were mainly suppressed with antipsychotic drugs. Thereafter, he had stayed in the psychiatric hospital in an air-conditioned room, and the temperature of which was maintained above 20°C. In February 2009, he experienced consciousness disturbance after breakfast. His axillary body temperature could not be obtained, and he was transferred to our hospital. The staff at the psychiatric hospital denied that he was exposed to a cold environment or overdosage of drugs before or after the hypothermic attack.
After arriving at our hospital, his core body temperature was 33.3°C without piloerection or shivering. His blood pressure was 99/54 mm Hg, and heart rate was 55 beats per minute. Neurologic examination revealed mild disturbance of consciousness. Results of routine laboratory tests were normal, except for mild hyponatremia (serum sodium of 133 mEq/L). Endocrine tests showed a free T4 level of 0.97 ng/dL, thyroid-stimulating hormone level of 0.42 μIU/mL, and adrenocorticotropic hormone level of 10.3 pg/mL. Brain MRI and whole-body CT were unremarkable. Therefore, sepsis, endocrine disease, and exposure to cold environment were excluded. He was diagnosed with moderate hypothermia associated with anti–LGI1 encephalitis based on the detection of LGI1 antibodies in his serum and CSF, and active rewarming was performed until his body temperature returned to normal. His body temperature recovered within 24 hours after hospitalization, and his level of consciousness ameliorated with the increase of body temperature. Hypothermic attacks with mild disturbance of consciousness occurred repeatedly 7 times, and he recovered by rewarming in each occasion; however, rewarming was not effective for preventing recurrences. We administered methylprednisolone pulse therapy which showed no effects. The mean recurrence interval of hypothermic attacks was 15.8 (5–37) days. After administration of the first course of IV immunoglobulin (IVIG), the recurrence interval increased to 79 days; and no hypothermic attacks occurred for 5 years after the second course of IVIG treatment.
Discussion.
The center of thermoregulation is in the hypothalamus. The effector mechanisms for cold defense include cutaneous vasoconstriction, piloerection, and heat production by means of shivering. Therefore, the absence of piloerection and shivering during hypothermia in our case suggested a dysfunction of the hypothalamus thermoregulatory center.
To better understand this clinical problem, we reviewed the reports of 6 patients with VGKC-complex or LGI1 antibody–associated encephalitis who presented with central hypothermia during the disease course, including the current patient (table).3,4 Almost all cases, except for a patient with continued hypothermia, developed single or dual attacks. Three or more repeated hypothermic attacks had not been previously reported in patients with anti–LGI1 encephalitis. The patients reported by Jacob et al.3 likely had anti–LGI1 encephalitis; however, encephalitis associated with contactin-associated protein–like 2 (Caspr2) antibodies cannot be ruled out because this type of VGKC-complex antibody can also associate with limbic encephalitis.5
Central hypothermia associated with VGKC or LGI1 antibody encephalitis including the present case
To the best of our knowledge, some patients with anti–NMDAR encephalitis can also develop hypothermia.6,7 The mechanism of hypothermia in autoimmune-mediated encephalitis is not clear. The LGI1 protein is widely expressed in the neurons of the CNS and also in the hypothalamus.2 The hypothermic attacks repeatedly occurred before effective immunotherapy. Therefore, we speculated that the hypothermic attacks were related to anti–LGI1 encephalitis. Although repeated hypothermic attacks are rare, it is important that clinicians are aware of these attacks that can occur during the course of anti–LGI1 encephalitis, as these attacks can be fatal if undetected or overlooked.
Acknowledgments
Acknowledgment: The authors thank Dr. Josep Dalmau for studying LGI1 antibody.
Footnotes
Author contributions: Dr. Hayashi: study concept and design, writing a paper, and patient care and cure. Dr. Yamada: patient care and cure. Dr. Kimura: management for clinical care and cure. Dr. Inuzuka: study supervision and management for clinical care and cure.
Study funding: No targeted funding reported.
Disclosure: Y. Hayashi received research support from The Ministry of Education, Culture, Sports, Science and Technology of Japan. M. Yamada and A. Kimura report no disclosures. T. Inuzaka received research support from Eizai Co, Dainippon Sumitomo Pharmaceutical Co, Takeda Pharmaceutical Co, Otsuka Pharmaceutical Co, GlaxoSmithKline, The Ministry of Health, Labour and Welfare of Japan, and The Ministry of Education, Culture, Sports, Science and Technology of Japan. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by the authors.
- Received February 13, 2017.
- Accepted in final form March 10, 2017.
- Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
- 1.↵
- 2.↵
- 3.↵
- Jacob S,
- Irani SR,
- Rajabally YA, et al
- 4.↵
- 5.↵
- van Sonderen A,
- Arino H,
- Petit-Pedrol F, et al
- 6.↵
- 7.↵
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Immunoadsorption therapy in autoimmune encephalitidesMüjgan Dogan Onugoren, Kristin S. Golombeck, Corinna Bien et al.Neurology - Neuroimmunology Neuroinflammation, February 26, 2016 -
Views and Reviews
Encephalitis and antibodies to synaptic and neuronal cell surface proteinsEric Lancaster, Eugenia Martinez-Hernandez, Josep Dalmau et al.Neurology, July 11, 2011 -
Article
Autoimmune Encephalitis Resembling Dementia SyndromesAnna E.M. Bastiaansen, Robin W. van Steenhoven, Marienke A.A.M. de Bruijn et al.Neurology: Neuroimmunology & Neuroinflammation, August 02, 2021 -
Article
Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitisMarienke A.A.M. de Bruijn, Agnes van Sonderen, Marleen H. van Coevorden-Hameete et al.Neurology, April 12, 2019